Dierynck I - Search Results

1

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies.

Hoetelmans RM, Dierynck I, Smyej I, Meyvisch P, Jacquemyn B, Marien K, Simmen K, Verloes R. Hoetelmans RM, et al. Among authors: dierynck i. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):299-305. doi: 10.1097/QAI.0000000000000011. J Acquir Immune Defic Syndr. 2014. PMID: 24121757 Clinical Trial.

2

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients.

Stellbrink HJ, Arastéh K, Schürmann D, Stephan C, Dierynck I, Smyej I, Hoetelmans RM, Truyers C, Meyvisch P, Jacquemyn B, Mariën K, Simmen K, Verloes R. Stellbrink HJ, et al. Among authors: dierynck i. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):283-9. doi: 10.1097/QAI.0000000000000003. J Acquir Immune Defic Syndr. 2014. PMID: 24121756 Clinical Trial.

3

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. Dierynck I, et al. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896904 Free PMC article.

4

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G. Lathouwers E, et al. Among authors: dierynck i. Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719. Antivir Ther. 2011. PMID: 21311113 Clinical Trial.

5

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP. De Meyer S, et al. Among authors: dierynck i. AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec. AIDS. 2009. PMID: 19474650 Clinical Trial.

6

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S. Blanche S, et al. Among authors: dierynck i. AIDS. 2009 Sep 24;23(15):2005-13. doi: 10.1097/QAD.0b013e328330abaa. AIDS. 2009. PMID: 19724191 Clinical Trial.

7

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.

Kesteleyn B, Amssoms K, Schepens W, Hache G, Verschueren W, Van De Vreken W, Rombauts K, Meurs G, Sterkens P, Stoops B, Baert L, Austin N, Wegner J, Masungi C, Dierynck I, Lundgren S, Jönsson D, Parkes K, Kalayanov G, Wallberg H, Rosenquist A, Samuelsson B, Van Emelen K, Thuring JW. Kesteleyn B, et al. Among authors: dierynck i. Bioorg Med Chem Lett. 2013 Jan 1;23(1):310-7. doi: 10.1016/j.bmcl.2012.10.095. Epub 2012 Nov 1. Bioorg Med Chem Lett. 2013. PMID: 23177258

8

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, de Béthune MP, Picchio G. Dierynck I, et al. Antivir Ther. 2010;15(8):1161-9. doi: 10.3851/IMP1697. Antivir Ther. 2010. PMID: 21149923 Clinical Trial.

9

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. De Meyer S, et al. Among authors: dierynck i. Hepatology. 2012 Dec;56(6):2106-15. doi: 10.1002/hep.25962. Hepatology. 2012. PMID: 22806681 Clinical Trial.

10

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.

Dierynck I, Ghys A, Witek J, Luo D, Janssen K, Daems B, Picchio G, Buti M, De Meyer S. Dierynck I, et al. J Viral Hepat. 2014 Dec;21(12):835-42. doi: 10.1111/jvh.12347. J Viral Hepat. 2014. PMID: 25402544 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters